Where the stock stands
The evidence pack for APLLTD, dated 11 August 2026, is unusual in what it leaves out. It carries no closing price, no session range, no traded volume and no return history, so any claim here about how the shares actually changed hands would be invention. What it does hold is a valuation block and a trail of exchange filings.
On valuation, the pack puts the price-to-earnings ratio at 23.74 - the multiple the market pays for each rupee of trailing profit - alongside a price-to-book of 2.91, earnings per share of 35.33 and a dividend yield of 1.43 per cent. The sector field reads "Unknown", so nothing here supports setting those multiples against an industry norm. One inconsistency is worth naming at the outset: the pack identifies the issuer only as APLLTD with an unknown sector, while every exchange filing it lists is made in the name Alembic Pharmaceuticals Limited.
What the smart-money flow shows
This is normally the section that carries the most weight, and here it is the thinnest. The pack contains no futures and options data at all - no open-interest change, no long buildup (fresh futures positions opened while the price is rising), no short buildup, no options chain. It lists no bulk or block deals, names no institutional buyer or seller, and gives no delivery-percentage series, no FII or DII buying streak and no insider or promoter-pledge filings.
That absence is a gap in the record rather than evidence of quiet positioning. It does not establish that no large investor traded the stock; it establishes only that this pack was assembled without those fields. Nor are these empty lists that would mark a genuinely blank day of large-trade reporting. The fields are simply not present, which is weaker information than a recorded zero.
The nearest thing to a governance signal is the filing trail set out below. Board and key-personnel changes are disclosures, not flows - they say who is leaving, never who is buying.
The technical picture
There is no technical picture to draw. The pack supplies no price series, no moving averages, no relative-strength reading, no volume profile and no 52-week range, so trend, momentum, support and resistance all sit outside what this data can address. The one market-level figure available, a Nifty move of 0.46 per cent lower on the as-of date, describes the index and says nothing about a single stock.
Catalysts and what to watch
The filing trail runs to six entries and splits cleanly in two. Three are tagged Key Resignation and flagged bearish. The most specific, dated 10 August 2026, reports the resignation of Ms Manisha Saraf as Company Secretary and Compliance Officer with effect from 11 August 2026, so the filing precedes the effective date. The other two use the exchange's generic wording about a Director, KMP or SMP stepping down, dated 10 and 11 August. Whether they describe the same departure or separate ones cannot be settled from what is here.
The remaining three are tagged Regulatory Approval and flagged bullish, and all relay the identical press release dated 28 July 2026, in which the company informed the exchange that it had received USFDA final approval for Prucalopride Tablets in 1 mg and 2 mg strengths. Those entries are dated 28, 29 and 30 July: three records of one announcement. The raw count overstates the news flow.
None of the six news headlines arrives with article text, so each is a title only. GuruFocus reported on quarterly earnings-call highlights, TradingView on a revenue breakdown, and simplywall.st on an upcoming dividend of 12.00 rupees per share. Two further headlines are analyst-forecast pieces, which this page excludes as a matter of policy.
What the data establishes is narrow: a valuation snapshot, one USFDA approval logged three times, and a cluster of key-personnel resignations inside the same week. What it does not establish is any connection between those events and the share price - because the price is not in the pack at all.